The once highly fragmented Indian pharmaceutical industry is undergoing strategic consolidations with the aim of emerging as a highly organized sector. With the inflow of MNCs' R&D operations the industry will continue to experience a trend of M&A. Deals and acquisitions are set to continue due to low-cost infrastructure and labor as patent expiries and the thin pipelines of major companies will cause revenues to fall.
The Indian government has implemented various initiatives to increase insurance coverage and reduce healthcare costs, such as the National Rural Health Mission and Jan Aushadhi. A revised pricing policy was also proposed in 2011, which will increase government control to over 60% of drugs.
Rising income levels, changing disease patterns, increasing reach of healthcare, reduced out-of-pocket expenditure and growth of new products such as generics and biosimilars are expected to drive growth in the future.
- Macroeconomic environment of the pharmaceutical industry in India, covering demographic analysis, drivers, and barriers
- Important industry characteristics, looking at healthcare policies, regulations, distribution, pricing, taxation, spending, insurance and reimbursement
- Market analysis of segments such as prescription medicines, biotechnology, over-the-counter medicines and Contract Research and Manufacturing Services (CRAMS)
- Annualized market data from 2005 to 2010 for important therapeutic segments
Copyright©2012 PR Newswire.
All rights reserved